Gallic Acid

Gallic Acid

SCHEMBL338356

O=C(O)c1cc(O)c(O)c(O)c1.[BiH3]

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.94
CA1 P00915 4/20 0.94
CA2 P00918 4/20 0.94
CA7 P43166 4/20 0.94
CA9 Q16790 4/20 0.94
CA14 Q9ULX7 4/20 0.94
KDM4E B2RXH2 4/20 0.94
MAPT P10636 3/20 0.94
CA4 P22748 3/20 0.94
CA6 P23280 3/20 0.94
LMNA P02545 3/20 0.94
TDP1 Q9NUW8 3/20 0.94
ALDH1A1 P00352 2/20 0.94
FUT7 Q11130 2/20 0.94
CA3 P07451 2/20 0.94
CA5A P35218 2/20 0.94
CA5B Q9Y2D0 2/20 0.94
TP53 P04637 1/20 0.94
SELL P14151 1/20 0.94
HPGD P15428 1/20 0.94

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gallic Acid SCHEMBL11242130 1.00 CA12 (0.94) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL27661465 0.97 CA12 (0.90) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL28045480 0.97 CA12 (0.90) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL27758718 0.97 CA12 (0.90) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL4276875 0.97 CA12 (0.90) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL28704043 0.97 CA12 (0.90) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL28331287 0.97 CA12 (0.90) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL3137007 0.97 CA12 (0.90) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL15012 0.97 CA12 (1.00) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL4918056 0.97 CA12 (1.00) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024022447-A1 USE OF BISMUTH-POLYMER COMPLEX IN DIGESTIVE TRACT VISUALIZATION 上海交通大学 2024-02-01 WO claimed
WO-2023063827-A1 SYNERGISTIC COMPOSITION AGAINST PSEUDOMONAS AERUGINOSA OMNICIN THERAPEUTICS B.V. (NL) 2023-04-20 WO claimed
CN-112267306-A Flame-retardant anti-static fabric and preparation method thereof 李东靖 2021-01-26 CN claimed
US-20200268769-A1 METHODS FOR TREATING HELICOBACTER INFECTION DEXCEL PHARMA TECHNOLOGIES LTD. (IL) 2020-08-27 US claimed
EP-3036194-B1 OPTICAL COMPOUNDS, USE AND METHOD FOR PRODUCING THEREOF BEP S R L (IT) 2019-03-27 EP claimed
CN-108325054-A Intra-cavity treatment system for gastrointestinal tract infection 刘泰成 2018-07-27 CN claimed
CN-107602897-A A kind of preparation method of gallic acid bismuth structure ferroelectric thin-flim materials 苏州云舒新材料科技有限公司 2018-01-19 CN claimed
US-9816029-B2 Organic amine decarbonization solutions CHINA PETROLEUM & CHEMICAL CORPORATION (CN) 2017-11-14 US claimed
EP-2768936-B1 FORMULATIONS, THEIR USE AS OR FOR THE MANUFACTURE OF DISHWASHING COMPOSITIONS, AND MANUFACTURE BASF SE (DE) 2017-03-01 EP claimed
WO-2016203431-A1 LUMINESCENT BISMUTH SILICATES, USE AND METHOD FOR PRODUCING THEREOF UNIVERSITA' CA' FOSCARI (IT) 2016-12-22 WO claimed
US-6436201-B1 RUST PROOFING UNTREATED STEEL PLATES OR SHEETS; RESIN SUCH AS AMINE ADDED EPOXY RESIN; BISMUTH, LANTHANUM OR MOLYBDENUM COMPOUND; MAGNESIUM OR ZINC ALUMINUM HYDROXIDE HYDRATE; SMOOTHNESS; LEAD AND CHROMIUM FREE; AUTOMOBILE UNDERCOATINGS KANSAI PAINT CO., LTD. (JP) 2002-08-20 US claimed
US-20020068836-A1 Reaction systems for making N- (phosphonomethyl) glycine compounds MONSANTO COMPANY 2002-06-06 US claimed
US-20020016503-A1 Use of a supplemental promoter in conjunction with a carbon-supported, noble-metal containing catalyst in liquid phase oxidation reactions MONSANTO TECHNOLOGY LLC 2002-02-07 US claimed
WO-2001092272-A2 REACTION SYSTEMS FOR MAKING N-(PHOSPHONOMETHYL)GLYCINE COMPOUNDS MONSANTO TECHNOLOGY LLC (US) 2001-12-06 WO claimed
EP-0910393-B1 AGENT FOR THE TOPICAL TREATMENT OF SKIN CONDITIONS LUFEN HANS (DE) 2001-12-05 EP claimed
WO-2001046208-A2 USE OF A SUPPLEMENTAL PROMOTER IN CONJUNCTION WITH A CARBON-SUPPORTED, NOBLE-METAL-CONTAINING CATALYST IN LIQUID PHASE OXIDATION REACTIONS MONSANTO TECHNOLOGY LLC (US) 2001-06-28 WO claimed
CN-1124136-A Apparatus and process for strengthening low density compression dosage units and product therefrom FUISZ TECHNOLOGIES LTD (US) 1996-06-12 CN claimed
US-5035973-A Image forming method and apparatus therefor KABUSHIKI KAISHA TOSHIBA (JP) 1991-07-30 US claimed
US-4670245-A ULCERS VASQUEZ TONY E 1987-06-02 US claimed
US-4298003-A System for delivering agent at zero order rate with emerging agent below saturation ALZA CORPORATION (US) 1981-11-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016503-A1 Use of a supplemental promoter in conjunction with a carbon-supported, noble-metal containing catalyst in liquid phase oxidation reactions GNMT, OGG1, NT5C3B CA12 1421/4885CA1 99/4885CA2 229/4885
US-20020068836-A1 Reaction systems for making N- (phosphonomethyl) glycine compounds GNMT, NPM1, OGA CA12 1027/4885CA1 730/4885CA2 626/4885
US-20200268769-A1 METHODS FOR TREATING HELICOBACTER INFECTION FUS, SI, NSF CA12 570/4885CA1 1262/4885CA2 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.